Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Limited ("Verdiva"), a clinical-stage biopharmaceutical company specialized in developing innovative treatments for obesity and other cardiometabolic disorders.

The partnered portfolio under this collaboration includes:

• Oral Ecnoglutide (Ecnoglutide Oral, XW004): A phase 2-ready, potential first-in-class, once-weekly oral GLP-1 receptor agonist
• Oral Amylin Receptor Agonist (Amylin RA): A potential first-in-class, once-weekly long-acting, oral amylin receptor agonist in IND-enabling studies
• Subcutaneous injectable Amylin Receptor Agonist (Amylin RA): A potential best-in-class, long-acting, amylin receptor agonist in IND-enabling studies

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea. Sciwind has retained the rights to develop，manufacture and commercialize these products in all other regions.

Under the agreement, Sciwind receives an upfront consideration totaling approximately $70 million, and is eligible to receive more than $2.4 billion in milestone payments for development, regulatory approvals and commercialization of above-mentioned partnered programs,. Additionally, Sciwind is also eligible to receive tiered royalties on future product sales outside of greater China and South Korea. Furthermore, the two companies will collaborate on additional preclinical stage programs, and Sciwind is eligible to receive milestones and royalty payments based on the advancement of those programs.

Verdiva Bio, led by industry experts and serial entrepreneurs, boasts a world-class drug development team with extensive experience in the global metabolic treatment sector. With this collaboration, Verdiva Bio plans to advance the development of innovative therapies through a series of clinical studies involving both monotherapy and combination treatments. This collaboration highlights the global commercialization potential of Sciwind's innovative pipeline and lays a solid foundation for the worldwide development and potential commercialization of key products like Ecnoglutide.